Trial · NCT03728933
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score | Placebo | -8.2 | Standard Deviation 6.8 | score on a scale | |
| Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score | Rotigotine 2 mg/24h | -14.0 | Standard Deviation 8.2 | score on a scale | |
| Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score | Rotigotine 3 mg/24h | -6.4 | Standard Deviation 5.8 | score on a scale | |
| Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period | Placebo | -1.0 | Standard Deviation 1.4 | score on a scale | |
| Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period | Rotigotine 2 mg/24h | -1.7 | Standard Deviation 1.1 | score on a scale | |
| Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period | Rotigotine 3 mg/24h | -0.8 | Standard Deviation 0.8 | score on a scale | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | 87.5 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rotigotine 2 mg/24h | 87.5 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rotigotine 3 mg/24h | 71.4 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals | Placebo | 12.5 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals | Rotigotine 2 mg/24h | 0 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals | Rotigotine 3 mg/24h | 0 | percentage of participants | ||
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Placebo | Satisfaction with sleep | -1.8 | Standard Deviation 4.1 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Rotigotine 2 mg/24h | Satisfaction with sleep | -4.7 | Standard Deviation 2.3 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Rotigotine 3 mg/24h | Satisfaction with sleep | -2.0 | Standard Deviation 2.8 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Placebo | Severity: RLS symptoms at falling asleep | -2.8 | Standard Deviation 3.6 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Rotigotine 2 mg/24h | Severity: RLS symptoms at falling asleep | -5.6 | Standard Deviation 1.6 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Rotigotine 3 mg/24h | Severity: RLS symptoms at falling asleep | -2.8 | Standard Deviation 1.8 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Placebo | Severity: RLS symptoms during the night | -1.0 | Standard Deviation 2.5 | score on a scale |
| Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period | Rotigotine 2 mg/24h | Severity: RLS symptoms during the night | -2.9 | Standard Deviation 3.0 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03728933/results